Core Viewpoint - The performance of the CES100 index, which reflects the overall performance of eligible securities under the "Hong Kong Stock Connect," has shown a decline of 15.20% over the past month, but an increase of 9.86% over the last three months and 7.13% year-to-date [1]. Group 1: Index Performance - The CES100 index closed flat with a trading volume of 0.0 billion [1]. - Over the past month, the CES100 index has decreased by 15.20% [1]. - The index has increased by 9.86% over the last three months and 7.13% year-to-date [1]. Group 2: Index Composition - The top ten holdings of the CES100 index include Alibaba-W (12.05%), Tencent Holdings (10.54%), HSBC Holdings (10.46%), Meituan-W (7.42%), Xiaomi Group-W (6.55%), AIA Group (5.25%), Hong Kong Exchanges and Clearing (3.75%), Standard Chartered Group (2.26%), Prudential (1.91%), and Kuaishou-W (1.35%) [2]. - The index is fully composed of securities from the Hong Kong Stock Exchange, with a 100% allocation [2]. - The sector allocation of the index includes Consumer Discretionary (30.43%), Financials (27.28%), Communication Services (14.16%), Information Technology (8.54%), Real Estate (4.93%), Utilities (4.45%), Consumer Staples (3.44%), Healthcare (3.33%), Industrials (2.94%), and Materials (0.49%) [2]. Group 3: Tracking Funds - Public funds tracking the CES100 index include Huaan CES Hong Kong Stock Connect Selected 100 ETF Link A, Huaan CES Hong Kong Stock Connect Selected 100 ETF Link C, and Huaan CES Hong Kong Stock Connect Selected 100 ETF [2].

Core Viewpoint - The China Securities Index Hong Kong Stock Connect Overseas 50 Index has shown a decline of 8.85% over the past month, while it has increased by 1.31% over the last three months and decreased by 0.09% year-to-date [1] Group 1: Index Performance - The current value of the China Securities Index Hong Kong Stock Connect Overseas 50 Index is reported at 2363.02 points [1] - The index was established on November 14, 2014, with a base value of 3000.0 points [1] Group 2: Index Holdings - The top ten weighted stocks in the index include HSBC Holdings (11.19%), Hong Kong Exchanges and Clearing (10.96%), AIA Group (9.61%), Standard Chartered (8.31%), Prudential (7.05%), Techtronic Industries (4.58%), CLP Holdings (4.3%), Bank of China (Hong Kong) (4.07%), CK Hutchison Holdings (3.72%), and Sun Hung Kai Properties (3.38%) [1] - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange [1] Group 3: Industry Composition - The industry composition of the index shows that financials account for 55.33%, real estate for 11.96%, utilities for 10.48%, consumer discretionary for 10.47%, communication services for 4.98%, industrials for 2.92%, consumer staples for 2.47%, information technology for 0.53%, healthcare for 0.44%, and energy for 0.41% [2] Group 4: Sample Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - New samples ranked within the top 40 are prioritized for inclusion, while those ranked below 60 are prioritized for removal [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample is delisted or when a new overseas company meets the criteria for inclusion [2]

智通财经APP获悉，核药龙头再添重磅产品新进展！4月21日，远大医药(00512)公布其用于诊断肝细胞癌(HCC)的全球创新放射性核素偶联药物(RDC) GPN02006在中国开展的研究者发起的临床研究（IIT临床研究）取得了里程碑式突破，并于成都2025未来XDC新药大会中公开发表了临床结果—— GPN02006给药后30分钟即可实现高质量显像，其显像背景信号极低，可实现HCC病灶特异性高摄取，且拥有优异的诊断对比度，临床优势显著。 GPN02006可为临床医生制定个体化诊疗方案提供强有力的分子影像学依据，充分满足肝细胞癌临床快速诊断需求，并有望改善当前HCC患者早期诊断率不 足及复发转移监测困难的临床现状。 此次研究进展标志着远大医药在抗肿瘤核药研发领域再次取得重大突破，进一步巩固了公司在放射性诊疗一体化领域的领先地位。 前瞻性布局GPC-3靶点，积极临床结果体现产品潜力 根据公告，GPN02006是远大医药合作开发的全球创新、基于放射性核素-抗体偶联技术的靶向磷脂酰肌醇蛋白聚糖3 (GPC-3)的诊断型放射性药物，其对 GPC-3靶点具有高特异性和高亲和力，且安全性好，适用对HCC的精准诊断，GPC3在 ...

目前，临床上HCC诊断的金标准依旧是病理组织学和/或细胞学检查，但由于该方法为有创性检查，使 用受到诸多条件限制，因此一般不作为首选的初诊方式。目前主流的首选诊断方法主要是血清学肿瘤标 志物检测和常规的影像学检测，但是我国HCC患者大多伴随基础肝病，超过80%的HCC发生在肝硬化基 础上，不典型增生结节或肝硬化背景使肝脏占位鉴别诊断困难而"辨不准"，因此，HCC 的精准诊断仍 面临着较大的挑战。近年来，以核医学为代表的分子影像检测技术发展迅速，其应用放射性药物与疾病 发生发展过程中的生物标志物特异性结合或参与生物代谢，在分子水平实现无创可视和量化评价而用于 疾病诊断，最常用的是氟-18-氟代去氧葡萄糖(F-FDG)PET 显像，然而，F-FDG 并非肿瘤特异性显像 剂，且由于HCC细胞膜葡萄糖转运蛋白表达低，文献报告F-FDG PET显像对HCC诊断的灵敏度仅为 36%-70%，美国国立综合癌症网路(National Comprehensive Cancer Network，NCCN)发布的指南不推荐 F-FDG 用于HCC诊断和评估。因此，开发高靶向HCC特异性分子探针是HCC精准个体化诊疗的重要发 展趋势 ...

Core Points - The China-Hong Kong-US Technology Index has shown a decline of 14.62% over the past month, 3.85% over the past three months, and 3.32% year-to-date [1] - The index is composed of high liquidity and high market capitalization technology companies listed in Hong Kong and the US, calculated using an equal-weighted method [1] - The index's top ten holdings include companies such as SMIC (3.61%), BYD (3.23%), and Alibaba (2.55%) [1] Market Composition - The Nasdaq Global Select Market accounts for 40.10% of the index, followed by the Hong Kong Stock Exchange at 36.04% and the New York Stock Exchange at 22.41% [2] - The industry breakdown of the index shows that Information Technology comprises 38.88%, Consumer Discretionary 20.37%, and Healthcare 14.75% [2] Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December [2] - New technology companies that rank in the top five by market capitalization in their respective regions will be quickly included in the index after their eleventh trading day [2]

金融界4月21日消息，上证指数低开高走，中证沪港深新生代消费主题指数 (SHS新生代消费，931765) 报1719.01点。 本文源自：金融界 作者：行情君 从中证沪港深新生代消费主题指数持仓样本的行业来看，可选消费占比41.55%、通信服务占比 33.35%、信息技术占比19.59%、主要消费占比3.85%、医药卫生占比1.64%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。当港股通证券范 围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 数据统计显示，中证沪港深新生代消费主题指数近一个月下跌16.03%，近三个月上涨9.98%，年至今上 涨5.99%。 据了解，中证沪港深新生代消费主题指数从内地与香港市场上市公司中，选取食品饮料、服饰装扮、休 闲娱乐以及其它生活用品及服务等领域中符合新生 ...

Core Viewpoint - The CSI Hong Kong-Shanghai-Macau Pharmaceutical R&D Service Index has shown a decline of 20.89% over the past month, while it has increased by 1.05% over the last three months and decreased by 2.89% year-to-date [1] Group 1: Index Performance - The CSI Hong Kong-Shanghai-Macau Pharmaceutical R&D Service Index is currently at 1344.91 points [1] - The index was established on December 29, 2017, with a base point of 1000.0 [1] Group 2: Index Composition - The top ten weighted companies in the index are: WuXi Biologics (18.47%), WuXi AppTec (13.28%), Hangzhou Tigermed Consulting (7.0%), and others [1] - The index consists of no more than 50 listed companies providing drug research, development, and production services [1] Group 3: Market Distribution - The market distribution of the index holdings is as follows: Shenzhen Stock Exchange (35.66%), Shanghai Stock Exchange (32.49%), and Hong Kong Stock Exchange (31.85%) [1] Group 4: Industry Breakdown - The industry composition of the index holdings includes: Pharmaceutical and Biotechnology Services (86.14%), Chemical Drugs (11.95%), Agricultural Chemicals (1.39%), and Biopharmaceuticals (0.52%) [2] Group 5: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Special circumstances may lead to temporary adjustments of the index [2]

Group 1 - Novo Nordisk and JD Health signed a strategic cooperation agreement on April 21, marking a new phase in their collaboration in diabetes and weight management [2] - Approximately 140 million adults in China suffer from diabetes, and around 180 million adults are obese, with rising prevalence rates [2] - The partnership aims to create a public awareness zone for obesity and facilitate one-stop diabetes treatment, enhancing the digital transformation of chronic disease management [2] Group 2 - The collaboration will establish a multi-party dialogue platform to improve accessibility and convenience of quality healthcare services [3] - Utilizing medical big data analysis and AI-assisted diagnosis systems, the partnership aims to develop a comprehensive smart healthcare solution covering the entire cycle from prevention to management [3]

Core Insights - RoboSense has launched a customizable digital lidar platform that supports up to 2160 lines, catering to various industries including smart vehicles and robotics [1] - The new platform includes one-dimensional, two-dimensional, and array scanning capabilities, allowing for rapid adaptation to market needs [1] - In 2023, RoboSense has introduced multiple new products, including the E1R and Airy for service robots, as well as the EM4 and EMX for automotive applications [1]

【环球网财经综合报道】近期，2025年世界互联网大会亚太峰会的举办，标志着这座城市正从传统金融中心向"数字金融创新策源地"加速转 型。这一转型背后，是全球金融科技行业正以18.7%的年复合增长率(CAGR)高速扩张，2024年市场规模突破8.5万亿美元。其中，亚太地区以 45%的份额领跑，中国贡献1.9万亿美元，成为全球增长核心引擎。 自2018年起，金融壹账通以"技术+业务"双轮驱动战略，将业务版图扩展至20个国家和地区，累计服务197家境外金融机构。 有机构认为，2025年，AI大模型、量子计算、区块链+物联网成为技术升级的关键词。生成式AI已重塑智能客服、合规审计等场景，准确率突 破85%;量子加密技术进入实验室验证阶段，2030年或带来百倍算力提升。 在此背景下，一些企业捕捉这一战略窗口，选择香港作为"业务出海"的桥头堡，金融壹账通便是其中之一。作为中国平安集团唯一对外金融科 技输出窗口，金融壹账通率先布局，形成"政策+市场+技术"的三维驱动模式，深耕香港、辐射亚太、服务全球的出海布局。 具体来看，2023年11月，由金融壹账通技术支持的IPO智能结算平台FINI正式启用。此外，其EKYC-香港身份证 ...